top of page
OVA mRNA (Unmodified)
​Ovalbumin (OVA) mRNA (Unmodified) is a synthetic messenger RNA encoding the ovalbumin protein, the predominant glycoprotein found in egg whites. This mRNA is optimized for high expression levels and incorporates N1-methylpseudouridine (Unmodified) modifications to enhance translation efficiency and reduce immunogenicity. It is capped with a Cap-1 structure and includes a poly(A) tail, mimicking fully processed mature mRNA. OVA mRNA (Unmodified) serves as an excellent tool for immunology research, vaccine development, and studies involving antigen presentation and immune responses. ​
 
WARNING: This product is not for human or veterinary use.
 
Available QC Assays
 
Concentration
Standard, UV-Vis
A260/280Standard, UV-Vis
IntegrityStandard, Fragment Analysis by Capillary Electrophoresis
AppearanceStandard
EndotoxinStandard, < 10EU/mg
PurityIP-RP-HPLC
RNA Aggregation AssaySEC-HPLC
DNA SequencingSanger Sequencing
dsRNA ContentELISA
 

OVA mRNA (Unmodified)

PriceFrom $200.00
Quantity

  • OVA mRNA (Unmodified) is a synthetic messenger RNA encoding Ovalbumin (OVA), a widely studied model antigen derived from Gallus gallus (chicken egg white). This mRNA is designed for high-efficiency translation in mammalian cells and is widely used in immunology research, antigen presentation studies, vaccine development, and cancer immunotherapy.

     

    Our OVA RNA product is designed to provide researchers with a high-quality and reliable source of this critical tool for their experiments. For research use-only.

     

    Description

    Product Name

    		 Ovalbumin (OVA) mRNA
    Length 1450 nt
    Modifications N1-methyl-pseudouridine (Unmodified)
    Appearance Clear, Colorless Solution
    Buffer 1mM Sodium Citrate, pH 6.4
    Purity >90%, Fragment analysis by capillary gel electrophoresis
    Concentration ~1 mg/mL 
    A260/280 ~2.0
    Endotoxin <10 EU/mg
    Storage ≤ -40°C
    Shipping Method Dry Ice

     

    • Immunotherapy Research: Used as a model antigen for developing mRNA-based cancer vaccines.
    • Antigen Presentation Studies: Investigates MHC-I and MHC-II antigen presentation pathways in dendritic cells and T-cell activation.
    • In Vivo and In Vitro Studies: Evaluates mRNA delivery, expression kinetics, and immune response in preclinical models.
    • Cell Transfection & mRNA-LNP Formulation: Compatible with lipid nanoparticles (LNPs) for efficient delivery in cells and animal models.
bottom of page